But Eli Lilly may be starting to gain an edge over its Danish competitor in the two-horse race to capitalize on the soaring demand for those treatments, also known as GLP-1s.
Feeling out of the loop? We'll catch you up on the Chicago news you need to know. Sign up for the weekly Several analysts were particularly pleased with Eli Lilly's positive manufacturing updates. Demand for weight loss and diabetes drugs is outstripping supply in the U.S., so companies that can quickly get more of a product to patients can gain an edge in the space.
The analysts said there could still be intermittent supply shortages of Mounjaro and Zepbound in the near term"as access improves and physicians get more comfortable with the availability of supply." But they applauded Eli Lilly's progress towards beefing up its manufacturing footprint and supply. Ricks said Eli Lilly's ability to scale up manufacturing of Zepbound and Mounjaro makes the company confident it can compete with newcomers to the weight loss and diabetes drug market that may not have the same capacity."You're talking about making things on the billion scale, which takes time and is technically difficult and very capital-intensive," he continued."So, of course, competitors will have to come.
الإمارات العربية المتحدة أحدث الأخبار, الإمارات العربية المتحدة عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: Medscape - 🏆 386. / 55 اقرأ أكثر »